Serum HER2 as a Response Indicator to Various Chemotherapeutic Agents in Tissue HER2 Positive Metastatic Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aim of study was to evaluate the usefulness of serum HER2 as a therapeutic response indicator in patients with HER2 positive metastatic breast cancer (MBC). Materials and Methods: The levels of serum HER2 and CA15.3 were assayed in 148 serial serum samples from 50 HER2 positive MBC patients at both the baseline and follow-ups. The changes in the levels of serum HER2 and CA15.3 in relation to the tumor responses to the various chemotherapy regimens were monitored. Results: The levels of serum HER2 and CA15.3 were elevated in 82% and 62% of tissue HER2 positive patients, respectively, prior to therapies, with the changes in both tumor markers showing statistical significance in relation to the tumor responses (p＜0.01) in patients with elevated baseline serum markers. Conclusion: The level of serum HER2 could be a valuable response indicator, not only for trastuzumab containing therapy, but also for other common MBC chemotherapeutic agents. Also, as it is more frequently elevated, the serum level of HER2 may also be a more useful tumor marker than CA15.3 in HER2 positive MBC. (Cancer Res Treat. 2006;38:35-39)
Abstract
Purpose: The aim of study was to evaluate the usefulness of serum HER2 as a therapeutic response indicator in patients with HER2 positive metastatic breast cancer (MBC). Materials and Methods: The levels of serum HER2 and CA15.3 were assayed in 148 serial serum samples from 50 HER2 positive MBC patients at both the baseline and follow-ups. The changes in the levels of serum HER2 and CA15.3 in relation to the tumor responses to the various chemotherapy regimens were monitored. Results: The levels of serum HER2 and CA15.3 were elevated in 82% and 62% of tissue HER2 positive patients, respectively, prior to therapies, with the changes in both tumor markers showing statistical significance in relation to the tumor responses (p＜0.01) in patients with elevated baseline serum markers. Conclusion: The level of serum HER2 could be a valuable response indicator, not only for trastuzumab containing therapy, but also for other common MBC chemotherapeutic agents. Also, as it is more frequently elevated, the serum level of HER2 may also be a more useful tumor marker than CA15.3 in HER2 positive MBC. (Cancer Res Treat. 2006;38:35-39)
참고문헌 (25)
- "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease", 17, pp.2639~48 (1999)
- "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", 344, pp.783~92 (2001)
- "The neu (c-erbB-2) oncogene", 16, pp.148~55 (1989)
- "A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells", 6, pp.639~43 (1991)
- "The extracellular domain of p185", neu is released from the surface of human breast carcinoma cells,SK-BR-3, 1991, pp.266, 1716~20
- "Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients", 10, pp.1436~43 (1992)
- "Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients", 43, pp.87~95 (1997)
- "Plasma c-erbB-2 levels in breast cancer patients:prognostic significance in predicting response to chemotherapy", 16, pp.2409~16 (1998)
- "Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer", 6, pp.2356~62 (2000)
- "Circulating HER-2", erbB-2, pp.2001, 7[DOI]
- "Elevated serum Her-2", neu level predicts decreased response to hormone therapy in metastatic breast cancer, 2002, pp.20, 1467~72
- "Tumour marker measurements in the diagnosis and monitoring of breast cancer", 26, pp.91~102 (2000)
- "Circulating tumour markers in breast cancer", 31(1), pp.15~22 (2004)
- "Is circulating HER-2 more than just a tumor marker", 7, pp.2605~7 (2001)
- "Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse", 89, pp.329~36 (2000)
- "Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm", 21, pp.2889~95 (2003)
- "Clinical utility of serum HER-2", neu testing on the Bayer Immuno 1 automated system in breast cancer, 2001, pp.21, 1465~70
- "Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients", 75, pp.97~106 (2002)
- "The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer", 35, pp.47~53 (1999)
- "Relationship of serum HER-2", neu and serum CA 15-3 in patients with metastatic breast cancer, 2002, pp.48, 1314~20
- "High levels of serum HER-2", neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer, 2003, pp.9, 4423~34
- "Biweekly paclitaxel plus gemcitabine in advanced breast cancer:phase II trial and predictive value of HER2 extracellular domain", 15, pp.201~6 (2004)
- "Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2", neu monoclonal antibody plus cisplatin in patients with HER2, pp.1998, 16[DOI]
- "Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer", 20, pp.1800~8 (2002)
- "Monitoring of serum Her-2", neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer, 2004, pp.10, 1618~24